Author

Dean A Lee

Nationwide Children's Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

Aharon G. FreudiD· 1 shared Aleksandr IanevskiiD· 1 shared Anna E. VilgelmiD· 1 shared Anna Näätänen· 1 shared Arjun MittraiD· 1 shared Bridget A. OppongiD· 1 shared Constantine S. MitsiadesiD· 1 shared Diana SchenkweiniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aharon G. FreudORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins

Yinchong Wang, Evdokiya Reshetnikova, Nar Bahadur Katuwal, Vijaya Bharti, Marcelo SF Pereira, Bridget A. Oppong, Dean A Lee, Arjun Mittra, Aharon G. Freud, Anna E. Vilgelm

This paper shows CDK4/6 inhibitors make breast cancer cells more susceptible to NK cell therapy by increasing surface proteins that NK cells recognize.

bioRxiv · Apr 22, 2026 · PreprintCancer Biology

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface

Jonas Bouhlal, Emmi Jokinen, Petra Johanna Nygren, Diogo Dias, Aleksandr Ianevski, Jay Klievink, Hanna Lähteenmäki, Salomé Decombis, Hanna Duàn, Emmi Järvelä, Emma Saarinen, Anna Näätänen, Konstantin Matjusinski, Tiina Kasanen, Tiina Hannunen, , Satu M. Mustjoki

The paper identifies drugs that rewiring the cancer-immune interface by enhancing NK cell function and tumor susceptibility through multimodal screening approaches.

bioRxiv · Apr 17, 2026 · PreprintCancer Biology